• Strong Sales Growth: US sales increased by ~100% in 2024 vs 2023
• Global Expansion: New distribution agreements in Hong Kong, Macau, and Middle East
• Clinical Advancements: Positive animal study results for NervAlign® Nerve Guide Matrix

ReNerve Limited (ASX:RNV), a medical device company focused on peripheral nerve repair, announced its half-year financial results for the six months ended 31 December 2024 (1HFY25). The company reported revenue of A$102,000 for 1HFY25, a significant 167% increase compared to the A$38,000 revenue in the prior corresponding period (1HFY24). Despite reporting a loss, ReNerve has made substantial progress, laying a strong foundation for future growth. The company closed the period with A$6.4 million in cash. Key highlights include strong sales growth in the US, with sales increasing by approximately 100% in 2024 compared to 2023. ReNerve also secured new distribution agreements with Accession Medical Supplies (Hong Kong & Macau) and Union MediScience B.S.C. (Middle East, covering six countries), complementing its existing partnerships in New Zealand and Taiwan. On the clinical front, the company's NervAlign® Nerve Guide Matrix demonstrated positive animal study results, showing comparable efficacy to autologous nerve grafts. Additionally, a clinical study evaluating the NervAlign® Nerve Cuff for nerve recovery post nerve repair is ongoing, with data expected in March 2025. The company also successfully completed its IPO, raising A$7 million (before costs) and listing on the ASX on 26 November 2024, providing funds for growth initiatives. ReNerve remains focused on expanding its US sales, driving international growth, advancing clinical programs, and progressing the development of its NervAlign® Nerve Conduit and Nerve Guide Matrix programs.

ReNerve remains focused on: - Expanding US sales through strategic partnerships and marketing initiatives - Driving international growth via established distribution networks - Advancing clinical programs to generate supporting data for NervAlign® products - Progressing the development of the NervAlign® Nerve Conduit and Nerve Guide Matrix programs